Get the Stockscreener App
14.50
0.41%
-0.06
After Hours:
14.50
Neuropace Inc stock is traded at $14.50, with a volume of 207.60K.
It is down -0.41% in the last 24 hours and down -14.25% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$14.56
Open:
$14.74
24h Volume:
207.60K
Relative Volume:
0.93
Market Cap:
$482.96M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-11.42
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
-6.39%
1M Performance:
-14.25%
6M Performance:
+58.82%
1Y Performance:
+19.93%
1-Day Range:
$14.02
$14.74
1-Week Range:
$14.02
$15.97
52-Week Range:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
14.50 | 484.96M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
Essex Investment Management Co. LLC Raises Holdings in NeuroPace, Inc. $NPCE - MarketBeat
How Does NeuroPace's Personalized Technology Transform Seizure Control - Kalkine Media
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Intraday: Is NeuroPace Inc a stock for growth or value investorsBond Market & High Conviction Buy Zone Alerts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Analysis: Exploring the 25.89% Potential Upside and Analyst Optimism - DirectorsTalk Interviews
Trading Systems Reacting to (NPCE) Volatility - Stock Traders Daily
How NeuroPace (NPCE) Analysts Are Quietly Rewriting The Story Behind The Stock - Yahoo Finance
NeuroPace stock price target raised to $20 from $19 at Leerink Partners By Investing.com - Investing.com Australia
NeuroPace stock price target raised to $20 from $19 at Leerink Partners - Investing.com Nigeria
Neuropace, Inc. (NPCE) Investor Outlook: A Medical Device Innovator with 26% Potential Upside - DirectorsTalk Interviews
FY2025 EPS Estimates for NeuroPace Lifted by HC Wainwright - MarketBeat
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright - Investing.com Nigeria
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright By Investing.com - Investing.com Canada
Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock - Benzinga
NeuroPace price target raised to $19 from $18 at H.C. Wainwright - TipRanks
Juniper Biomedical Appoints Frank Fischer To Board - citybiz
CORRECTING and REPLACING Juniper Biomedical Wins Neuromod Prize and Welcomes Frank Fischer to Board of Directors - The AI Journal
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
NeuroPace sees Q4 revenue of about $26.6M - MSN
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue - Investing.com Australia
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue By Investing.com - Investing.com South Africa
US-based NeuroPace revenue expected to grow 24% in Q4 2025 - Medical Buyer
Profit Recap: Will NeuroPace Inc stock benefit from M AWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
NeuroPace reports 25% revenue growth for 2025, projects steady growth By Investing.com - Investing.com Nigeria
NeuroPace Reports Preliminary Q4, 2025 Revenue; Sets 2026 Guidance - marketscreener.com
NeuroPace (NASDAQ:NPCE) Shares Gap UpShould You Buy? - MarketBeat
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Investing News Network
NeuroPace, Inc. Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2026 - marketscreener.com
NeuroPace reports 25% revenue growth for 2025, projects steady growth - Investing.com
NeuroPace (NASDAQ:NPCE) and Envoy Medical (NASDAQ:COCH) Critical Comparison - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.4% – What’s Next? - Defense World
Neurological Implants Market to Reach USD 12.39 Billion by 2031 | - openPR.com
Neuropace, Inc. (NPCE) Investor Outlook: Exploring the 13.5% Potential Upside in Medical Devices - DirectorsTalk Interviews
NeuroPace (NASDAQ:NPCE) Shares Down 4.4%Should You Sell? - MarketBeat
How resilient is NeuroPace Inc. stock in market downturnsDay Trade & Safe Investment Capital Preservation Plans - ulpravda.ru
When Will NeuroPace, Inc. (NASDAQ:NPCE) Turn A Profit? - 富途资讯
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st
Financial Review: Vicarious Surgical (NYSE:RBOT) vs. NeuroPace (NASDAQ:NPCE) - Defense World
How NeuroPace Inc. stock performs in rate cut cyclesJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Is NeuroPace Inc. stock oversold or undervaluedMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Will NeuroPace Inc. stock benefit from green energy trendsWatch List & High Conviction Investment Ideas - ulpravda.ru
Why NeuroPace Inc. stock remains undervaluedGlobal Market Influence & Low Risk Capital Appreciation - Улправда
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
NeuroPace stock dips after pricing $65M share offering - MSN
Can NeuroPace Inc. stock deliver sustainable ROE2026 world cup usa national team third place match playmakers high defensive line expert forecast breakdown - ulpravda.ru
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
User | bigspringherald.comNeuropace, Inc.Common Stock (Nasdaq:NPCE) Stock Quote - FinancialContent
UBS Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):